Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
Adolescent
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Female
Humans
Imatinib Mesylate
/ administration & dosage
Japan
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Male
Middle Aged
Protein Kinase Inhibitors
/ administration & dosage
Registries
Retrospective Studies
Survival Rate
BCR-ABL1
Chronic myeloid leukemia (CML)
Early molecular response (EMR)
Overall survival (OS)
Tyrosine kinase inhibitor (TKI)
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
29
01
2019
accepted:
06
02
2019
revised:
05
02
2019
pubmed:
15
2
2019
medline:
18
4
2019
entrez:
15
2
2019
Statut:
ppublish
Résumé
We report the results of a multicenter observational study using the New TARGET system, in which the effectiveness and safety of tyrosine kinase inhibitors (TKIs) were evaluated in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. A total of 506 patients were enrolled between April 2010 and March 2013. Median age was 56 (range 18-92) years; 35% of patients were females. As the first-line therapy, 139 (27.9%), 169 (33.9%) and 144 (28.9%) patients were treated with imatinib, nilotinib, and dasatinib, respectively. Five-year progression-free survival (PFS) and overall survival (OS) were 93.8% and 94.5%, respectively. The OS curve was significantly superior for patients treated with second-generation TKIs than imatinib (P = 0.0068), and an early molecular response (EMR) at 3 months (BCR-ABL1 < 10%) was detected in 328 of 377 patients evaluated for molecular response. The PFS curve was significantly superior for patients with EMR than without (P < 0.0001). Although 12 patients experienced vascular adverse events, no new safety issues were observed in patients with adverse events. The results of this observational study demonstrated that treating newly diagnosed CML-CP patients with TKI results in satisfactory and reliable outcomes.
Identifiants
pubmed: 30762219
doi: 10.1007/s12185-019-02613-1
pii: 10.1007/s12185-019-02613-1
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
426-439Investigateurs
M Kizaki
(M)
S Mori
(S)
T Nemoto
(T)
M Sagawa
(M)
T Tabayashi
(T)
M Tokuhira
(M)
T Tomikawa
(T)
R Watanabe
(R)
Y Hatta
(Y)
Y Inoue
(Y)
N Iriyama
(N)
S Kobayashi
(S)
Y Kobayashi
(Y)
D Kurita
(D)
D Karigane
(D)
H Kasahara
(H)
Y Koda
(Y)
Y Miyakawa
(Y)
K Murakami
(K)
S Okamoto
(S)
S Watanuki
(S)
T Ono
(T)
Y Nagata
(Y)
A Takeshita
(A)
N Takahashi
(N)
Y Kameoka
(Y)
T Yoshioka
(T)
S Takahashi
(S)
N Usui
(N)
K Dan
(K)
K Inokuchi
(K)
K Nakamura
(K)
D Abe
(D)
C Nakaseko
(C)
C Ohwada
(C)
E Sakaida
(E)
N Shimizu
(N)
M Takeuchi
(M)
S Arai
(S)
Y Kogure
(Y)
A Koya
(A)
Y Masamoto
(Y)
A Masuda
(A)
K Nakazaki
(K)
K Toyama
(K)
Y Hiroshima
(Y)
N Ichikawa
(N)
T Kirihara
(T)
H Kobayashi
(H)
I Shimizu
(I)
M Sumi
(M)
T Ueki
(T)
S Hagiwara
(S)
R Hirai
(R)
T Miwa
(T)
F Nakamura
(F)
M Nakamura
(M)
M Takeshita
(M)
A Tanimura
(A)
F Hayakawa
(F)
Y Ishikawa
(Y)
H Kiyoi
(H)
M Murata
(M)
A Tomita
(A)
T Kurokawa
(T)
C Sugimori
(C)
A Arai
(A)
O Miura
(O)
M Yamamoto
(M)
K Imai
(K)
N Kobayashi
(N)
K Minauchi
(K)
M Obara
(M)
S Ota
(S)
T Ikezoe
(T)
M Mori
(M)
M Sakai
(M)
A Taniguchi
(A)
K Togitani
(K)
H Hayakawa
(H)
T Kajiguchi
(T)
S Kamoshita
(S)
E Otsuka
(E)
A Nishida
(A)
M Saburi
(M)
Y Saburi
(Y)
H Iida
(H)
C Kato
(C)
Y Kojima
(Y)
H Ohashi
(H)
Y Miyata
(Y)
K Sugimoto
(K)
H Yamamoto
(H)
T Yokozawa
(T)
T Kamae
(T)
J Kuyama
(J)
H Mitsui
(H)
Y Morikawa
(Y)
Y Uchida
(Y)
T Ashida
(T)
C Hirase
(C)
K Kawanishi
(K)
I Matsumura
(I)
J Miyatake
(J)
Y Morita
(Y)
T Sano
(T)
T Shimada
(T)
H Tanaka
(H)
Y Taniguchi
(Y)
Y Tatsumi
(Y)
K Yamaguchi
(K)
F Ishida
(F)
K Momose
(K)
H Nakazawa
(H)
S Nishina
(S)
H Sakai
(H)
N Sekiguchi
(N)
Y Ito
(Y)
K Ohyashiki
(K)
T Tauchi
(T)
T Hata
(T)
Y Imaizumi
(Y)
D Imanishi
(D)
H Itonaga
(H)
J Makiyama
(J)
Y Sawayama
(Y)
J Taguchi
(J)
M Taguchi
(M)
H Taniguchi
(H)
G Eguchi
(G)
M Matsuda
(M)
N Yamairi
(N)
N Fukushima
(N)
K Ozeki
(K)
A Kohno
(A)
T Sakura
(T)
S Takada
(S)
T Kobayashi
(T)
H Sakamaki
(H)
N Asou
(N)
T Kawaguchi
(T)
T Kiguchi
(T)
T Masunari
(T)
N Sezaki
(N)
M Iino
(M)
K Morinaga
(K)
K Ikeda
(K)
K Ogawa
(K)
H Noji
(H)
H Iwasaki
(H)
K Takenaka
(K)
T Miyamoto
(T)
H Handa
(H)
H Murakami
(H)
N Tsukamoto
(N)
T Eto
(T)
H Henzan
(H)
Y Kamitsuji
(Y)
N Uoshima
(N)
M Hagihara
(M)
H Takahashi
(H)
N Emi
(N)
M Okamoto
(M)
K Kawakami
(K)
M Waki
(M)
N Fukuhara
(N)
H Harigae
(H)
T Murayama
(T)
I Mizuno
(I)
H Okumura
(H)
Y Tsutsumi
(Y)
K Usuki
(K)
T Fujisaki
(T)
Y Maeda
(Y)
Y Suehiro
(Y)
H Suzushima
(H)
K Yamamoto
(K)
Y Kanakura
(Y)
K Nagasaki
(K)
H Muto
(H)
S Fujisawa
(S)
M Adachi
(M)
A Mugitani
(A)
S Yamasaki
(S)
Y Adachi
(Y)
T Kamimura
(T)
Y Takamatsu
(Y)
T Ryu
(T)
S Chiba
(S)
K Ohishi
(K)
K Suzuki
(K)
D Ogawa
(D)
H Mihara
(H)
H Fujita
(H)
K Kubo
(K)
A Yokota
(A)
K Miyamura
(K)
C Yoshida
(C)
S Nakachi
(S)
T Myojyo
(T)
A Kitabayashi
(A)
J Suzumiya
(J)
M Hino
(M)
A Wakita
(A)
T Shibata
(T)
T Takahashi
(T)
H Takamatsu
(H)
K Fujimaki
(K)
K Tajika
(K)
M Mita
(M)
Y Terui
(Y)
M Ito
(M)
T Yamane
(T)
T Yamauchi
(T)
Y Kohara
(Y)
C Takebayashi
(C)
A Inagaki
(A)
M Tsuji
(M)
H Shinzaki
(H)
Y Moriuchi
(Y)
M Ishikawa
(M)
K Miyazaki
(K)
E Shima
(E)
N Kinugawa
(N)
Références
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Int J Hematol. 2008 Nov;88(4):409-417
pubmed: 18953513
N Engl J Med. 2010 Jun 17;362(24):2251-9
pubmed: 20525993
N Engl J Med. 2010 Jun 17;362(24):2260-70
pubmed: 20525995
Leuk Res. 2011 May;35(5):585-90
pubmed: 21145591
Leukemia. 2012 Sep;26(9):2096-102
pubmed: 22446502
Blood. 2013 Jun 13;121(24):4867-74
pubmed: 23620574
Blood. 2014 Jan 23;123(4):494-500
pubmed: 24311723
Blood. 2015 Feb 5;125(6):901-6
pubmed: 25525119
Leuk Lymphoma. 2016;57(6):1300-10
pubmed: 26373533
Leukemia. 2016 May;30(5):1044-54
pubmed: 26837842
JAMA Oncol. 2016 Feb 4;:null
pubmed: 26847662
Blood. 2016 Jul 7;128(1):17-23
pubmed: 27013442
J Clin Oncol. 2016 Jul 10;34(20):2333-40
pubmed: 27217448
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
Int J Hematol. 2017 Jun;105(6):792-804
pubmed: 28341918
Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51
pubmed: 28881915
Int J Hematol. 2018 Mar;107(3):327-336
pubmed: 29076005
Ann Hematol. 2018 Nov;97(11):2081-2088
pubmed: 29946911